Plasmin Activity Enhancement for Soft Tissue Calcification Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for preventing soft tissue calcification, such as bisphosphonates, have adverse effects and disrupt bone integrity and regeneration, and there is a need for a compound or method that can protect against pathological muscle calcification while promoting normal bone biology.
Innovation Solution
Administering a downregulator of plasmin inhibitors, such as α2-antiplasmin antisense oligonucleotides, or recombinant plasmin(ogen) to increase plasmin activity, which reduces or prevents soft tissue calcification by limiting dystrophic calcification and promoting muscle regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If bisphosphonates are used to prevent soft tissue calcification, then calcification is reduced, but bone integrity and regeneration are disrupted
Solution Approach 1:
The patent introduces plasmin as an intermediary substance that selectively prevents soft tissue calcification through its fibrinolytic activity, while leaving bone integrity unaffected. Plasmin acts as a mediator that targets the fibrin-rich environment of soft tissue calcification without interfering with bone remodeling processes, thus resolving the contradiction between preventing calcification and maintaining bone health
Solution Approach 2:
The patent applies local quality by targeting plasmin activity specifically to soft tissue environments where calcification occurs, rather than systemically affecting bone metabolism. By localizing the therapeutic effect to fibrin-rich soft tissues through plasmin's selective fibrinolytic action, the treatment prevents calcification locally without disrupting bone integrity systemically
2Object-affected harmful factors
If plasmin activity is increased to prevent calcification, then soft tissue calcification is reduced, but potential adverse effects on bone may occur
Solution Approach 1:
The patent employs self-service by utilizing the body's own plasminogen-activated plasmin system to prevent calcification. Rather than introducing external substances that might affect bone, the treatment activates the endogenous plasmin system that naturally protects against fibrin-rich calcification, allowing the body's own mechanisms to serve the protective function without external interference
Solution Approach 2:
The patent converts the potentially harmful effect of plasmin (which could theoretically affect bone) into a beneficial effect by controlling its activation specifically in soft tissue environments. The fibrinolytic activity that could potentially impact bone is instead harnessed to selectively degrade fibrin in soft tissues, transforming a potential harm into a beneficial calcification prevention mechanism
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively prevents soft tissue calcification and heterotopic ossification by enhancing plasmin activity, promoting muscle regeneration, and maintaining bone health without the adverse effects of existing treatments.
Implementation Method 1
Plasmin(ogen) is a serine protease that activates and degrades fibrin
Data Source
AI summary
A method for reducing or substantially preventing soft tissue calcification is provided. The method includes administering at least one of a downregulator of at least one plasmin inhibitors and plasmin(ogen) to a subject in need thereof, wherein the at least one plasmin inhibitor includes alpha2-antiplasmin. Further disclosed is a method comprises administering the compound subsequent to muscle injury, and the method further comprising administering an antifibrinolytic.